Ray Blanchard
Research psychiatrist and sexologist
Ray Blanchard is a research psychiatrist whose typology of gender dysphoria — including his concept of autogynephilia — spent decades under sustained attack from trans activists. For Irish listeners navigating a healthcare system still developing its gender services, his evidence-based framework raises urgent questions about patient pathways, clinical honesty, and who gets to decide what research is permissible.
Ray Blanchard spent fifteen years at a gender identity clinic before his research became one of the most contested bodies of work in contemporary sexology. Working at the Clarke Institute of Psychiatry in Toronto — later the Centre for Addiction and Mental Health — he developed a typology distinguishing two distinct pathways to gender dysphoria in natal males: one rooted in same-sex attraction, the other in autogynephilia, a male's erotic orientation towards imagining himself as female. The distinction was clinically significant: the two groups presented differently and arguably required different clinical responses.
His findings became the focus of a sustained campaign to suppress them. When J. Michael Bailey popularised Blanchard's framework in The Man Who Would Be Queen (2003), trans activists coordinated efforts to discredit the research entirely. Blanchard, despite serving on the DSM-5 workgroup for sexual and gender identity disorders, found his work continually misrepresented as a denial of trans identity rather than a clinical description of patient subtypes. It is this history — what actually happened to the research, and why — that Stella O'Malley examines in Autogynephilia: The Study Activists Wanted Buried (#41).
For Irish listeners, that suppression has real consequences. Ireland's National Gender Service has operated under significant pressure, and the question of how clinicians assess patients — adults and adolescents alike — turns partly on which conceptual tools practitioners are permitted to reach for. Blanchard's core argument, that different patient groups need different clinical approaches, sits in sharp tension with a therapeutic culture that has sometimes treated diagnostic nuance as gatekeeping.
With the Cass Review prompting hard questions about evidence standards across the British Isles, Blanchard's decades-long career offers an object lesson in what happens when inconvenient data meets organised activism. For an Irish audience watching gender-medicine debates play out in Dáil committees, school corridors, and GP surgeries, his conversation with Stella O'Malley is a reminder that the research was always there — it was the permission to discuss it that was buried.
